Clinical Trial Update: Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating adding tivozanib to pembrolizumab after surgery for kidney cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma
• Renal Pelvis Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)
• Tivozanib (Fotivda) (tivozanib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC) | Phase 3 | Status: RECRUITING